Various data combined with our study suggest that 6-gingerol may be a safe and useful complementary therapy for ccRCC and warrant further investigation of its antitumor efficacy in vivo and in vitro, either alone or in combination with TK inhibitors and mTOR inhibitors. This evidence concerns the gene TKT and nonpapillary renal cell carcinoma.